Talking to Your Healthcare Provider

Partnering with your healthcare provider is an important part of managing a bleeding disorder. Good communication can help you and your treatment team make appropriate decisions about your treatment.

Here are helpful tips to guide your conversation with your healthcare provider so that you both get all the information you need:

  • Share information about any symptoms or treatment side effects you’ve experienced since your last visit. Keeping a journal between visits may help.
  • Ask questions and take notes before and during your visit. Jot down any answers and instructions you’re given.
  • Ask for educational materials, such as treatment or condition brochures.
  • After your visit, review your notes and other materials, and try doing some of your own research on bleeding disorder Web sites or in books.
  • Follow up with your healthcare provider if you have any questions or concerns.

Get the printable healthcare professional discussion guide that you can keep handy and take with you to doctor visits. This guide can serve as a conversation starter as you and the healthcare professional discuss von Willebrand disease (VWD) and treatment with Humate-P.

Taking an active role in your own healthcare can help you get the best care possible. Start by learning all you can about bleeding disorders and their diagnosis:

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P® is approved to treat and prevent bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P also treats spontaneous or trauma-induced bleeding episodes in adults and children with von Willebrand disease (VWD) and prevents excessive bleeding during and after surgery in patients with mild, moderate or severe VWD. Humate-P is not known to prevent spontaneous bleeding episodes.

Do not take Humate-P if you have had extreme sensitivity or an allergic response to antihemophilic or von Willebrand factor preparations. Your doctor will monitor you for events related to abnormal blood clotting.

Humate-P is made from human blood and could contain infectious agents. The risk that these agents may transmit disease cannot be completely eliminated, but has been reduced by screening plasma donors and testing donated plasma for certain viruses, and by inactivating and/or removing viruses during manufacturing.

In studies, more than 5% of patients reported the following adverse reactions to Humate-P: allergic/anaphylactic reactions, including hives, chest tightness, rash, itching, and swelling. The most common adverse reactions after surgery were bleeding at the wound or infusion site, and nosebleeds.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Young adults sitting on a bench interior page Mom and child walking together interior page Father and son playing soccer interior page Father and son flying a kite interior page

© CSL Behring 2018. The product information on this site is intended for US residents only. HUM / 10-11-0010(1) 8/2015